Physitrack (Q1 Review): Enters a new growth phase - Redeye

Physitrack’s Q1 2026 report confirms that the structural "SaaS-only" reset has successfully protected the bottom line, with the Group demonstrating resilient margins. While top-line expansion has recently been below ambitions, management has rebuilt the commercial team and refined its go-to-market approach, already yielding new enterprise wins. We expect this trend to become increasingly visible in the coming quarters, supported by the imminent Remote Therapeutic Monitoring (RTM) launch designed to reignite growth momentum.

Länk till analysen i sin helhet: https://www.redeye.se/research/1160112/physitrack-q1-review-enters-a-new-growth-phase?utm_source=finwire&utm_medium=RSS